Capricor Therapeutics, Inc. (CAPR)

NasdaqGS • Currently up 0.12 (+1.29%) in today's trading session

1 member of Congress has disclosed 6 trades in Capricor Therapeutics, Inc. (CAPR) via STOCK Act filings. The most recent disclosure was a purchase by Roger Marshall on 27 July 2017. Aggregate disclosed activity totals roughly $24K in purchases and $24K in sales (midpoint estimates from bracketed disclosure amounts).

Capricor Therapeutics, Inc. is currently trading at $9.40, positioned at 17% of its 52-week range ($2.96 – $40.37).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$9.40
24h Change
+0.12 (+1.29%)
52 Week Range
$2.96–$40.37
View on NASDAQ

Capricor Therapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for CAPR

Select to highlight on chart
5 transactions
Compliance: 0%
Roger Marshall27 Jul 201710 Aug 2018PurchaseStock$1,001 - $15,000N/A
Roger Marshall27 Jul 201710 Aug 2018SaleStock$1,001 - $15,000N/A
Roger Marshall27 Jul 20176 Aug 2018SaleStock$1,001 - $15,000N/A
Roger Marshall27 Jul 20176 Aug 2018PurchaseStock$1,001 - $15,000N/A
Roger Marshall27 Jul 201713 Aug 2020SaleStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$540.6M

Volume

2.56M

Beta

0.53

P/E Ratio

-3.84

Fundamentals

EPS

$-2.45

Div. Yield

-

Open

$9.40

Day Range

$9.26 – $9.81

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Linda Marbán
IPO Date
2007-02-13
Website
www.capricor.com

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which re...

Earnings

Next Report

Q3 2026

9 Nov

EPS Est.

$-0.14

Rev. Est.

$41.7M

Days Until

62

Recent Quarters

Q2 202614 Aug
EPS$-0.70
Miss 18.9%
Q1 202612 May
EPS$-0.59
Miss 7.3%
Q4 202512 Mar
EPS$-0.62
Miss 21.6%
Q3 202510 Nov
EPS$-0.54
Beat 0.0%
Q2 202511 Aug
EPS$-0.57
Miss 18.8%
Q1 202513 May
EPS$-0.53
Miss 60.6%
Q4 202419 Mar
EPS$-0.16
Beat 48.4%
Q3 202413 Nov
EPS$-0.38
Miss 5.6%
Q2 20247 Aug
EPS$-0.35
Beat 2.8%
Q1 202413 May
EPS$-0.31
Miss 181.8%
Q4 202329 Feb
EPS$-0.02
Beat 77.8%
Q3 202314 Nov
EPS$-0.25
Beat 13.8%
Q2 20237 Aug
EPS$-0.29
Beat 17.1%
Q1 202311 May
EPS$-0.31
Beat 3.1%
Q4 202215 Mar
EPS$-0.31
Beat 6.1%
Q3 202210 Nov
EPS$-0.26
Beat 10.3%
Q2 202210 Aug
EPS$-0.29
Miss 16.0%
Q1 202210 May
EPS$-0.32
Q4 202110 Mar
EPS$-0.26
Miss 36.8%
Q3 20219 Nov
EPS$-0.17
Beat 22.7%
Q2 202112 Aug
EPS$-0.21
Beat 8.7%
Q1 202113 May
EPS$-0.23
Q4 202011 Mar
EPS$-0.21
Miss 5.0%
Q3 202012 Nov
EPS$-0.20
Q2 20206 Aug
EPS$-0.23
Beat 37.8%
Q1 202014 May
EPS$-0.30
Beat 9.1%
Q4 201918 Mar
EPS$-0.34
Beat 0.0%
Q3 20197 Nov
EPS$-0.43
Beat 38.6%
Q2 20196 Aug
EPS$-0.59
Beat 26.3%
Q1 201913 May
EPS$-0.80
Beat 27.3%
Q4 201828 Mar
EPS$-1.10
Beat 31.3%
Q3 201813 Nov
EPS$-1.40
Beat 3.5%
Q2 20189 Aug
EPS$-1.40
Miss 12.0%
Q1 201810 May
EPS$-1.40
Miss 16.7%
Q4 201714 Mar
EPS$-1.10
Miss 10.0%
Q3 20178 Nov
EPS$-1.20
Beat 36.8%
Q2 201710 Aug
EPS$-1.60
Beat 11.1%
Q1 201715 May
EPS$-1.70
Miss 13.3%
Q4 201615 Mar
EPS$-1.40
Beat 41.7%
Q3 201610 Nov
EPS$-2.90
Miss 9.4%
Q2 201615 Aug
EPS$-2.60
Miss 8.3%
Q1 201612 May
EPS$-2.60
Miss 36.8%
Q4 201517 Mar
EPS$-2.10
Miss 10.5%
Q3 201512 Nov
EPS$-1.80
Beat 30.8%
Q2 201513 Aug
EPS$-1.90
Beat 26.9%
Q1 201512 May
EPS$-2.30
Miss 64.3%
Q4 201418 Mar
EPS$-1.60
Miss 23.1%
Q3 201413 Nov
EPS$-1.30
Beat 40.9%
Q2 201414 Aug
EPS$-1.30
Q1 201415 May
EPS$-1.00
Q4 201331 Mar
EPS$-3.68
Q3 201314 Nov
EPS$-1.49
Q2 201314 Aug
EPS$-1.57
Q1 201321 Jun
EPS$-1.37
Q3 201231 Dec
EPS$-2.35
Q2 201230 Sept
EPS$-6.57
Q2 201214 Aug
EPS$-4.11
Q1 201215 May
EPS$-20.00
Miss 33.3%
Q1 20122 Apr
EPS$-20.95
Q3 201114 Nov
EPS$-15.00
Miss 100.0%
Q2 201115 Aug
EPS$-15.00
Miss 200.0%
Q1 201116 May
EPS$-15.00
Miss 50.0%
Q4 201014 Mar
EPS$-10.00
Beat 53.9%
Q3 201012 Nov
EPS$-25.00
Miss 7.2%
Q2 201016 Aug
EPS$-25.00
Beat 25.0%
Q1 201014 May
EPS$-35.00
Miss 23.5%
Q4 20093 Mar
EPS$-30.00
Miss 20.0%
Q3 200912 Nov
EPS$-40.00
Miss 60.0%
Q2 200913 Aug
EPS$-50.00
Miss 33.3%
Q1 200914 May
EPS$-35.00
Beat 40.0%
Q4 20089 Mar
EPS$-60.00
Beat 7.7%
Q3 200813 Nov
EPS$-70.00
Beat 10.6%
Q2 200814 Aug
EPS$-80.00
Miss 39.1%
Q1 200815 May
EPS$-65.00
Miss 18.2%
Q4 200713 Mar
EPS$-50.00
Beat 47.4%
Q3 200714 Nov
EPS$-173.62
Q2 200719 Jul
EPS$-53.65
Q1 200714 May
EPS$-27.44
Q4 20067 Feb
EPS$-6.70
Q3 200614 Nov
EPS$-539.07
Q2 20063 Aug
EPS$-5.98
Q1 200615 May
EPS$-4.79
Q4 200531 Mar
EPS$-4.69
Q3 200521 Nov
EPS$-2.28
Q2 200522 Aug
EPS$-1.95
Q1 200516 May
EPS$-3.57
Q4 200430 Mar
EPS$-6.14
Q3 200419 Nov
EPS$-2.33
Q2 200416 Aug
EPS$-1.90
Q1 200417 May
EPS$-1.64
Q4 200330 Mar
EPS$-3.57
Q3 200313 Nov
EPS$-0.06
Q2 200314 Aug
EPS$-4.61
Q1 200322 May
EPS$-2.46
Q1 200315 Apr
EPS$-2.50
Q3 200214 Nov
EPS$-5.67
Q2 200214 Aug
EPS$-6.25
Q1 200217 May
EPS$4.10
Q1 200215 Apr
EPS$-1.87
Q2 200130 Sept
EPS$-3.14
Q1 200130 Jun
EPS$-3.70
Q4 200031 Mar
EPS$-6.05

6 politicians traded within 30 days

No dividend data available for this stock.

Stock Splits

Split History

5 Jun 2019Reverse Split
Ratio1:10
21 Nov 2013Reverse Split
Ratio1:50
13 Feb 2007Reverse Split
Ratio1:10

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about CAPR

Which members of Congress have traded CAPR?
1 member of Congress has disclosed 6 trade in Capricor Therapeutics, Inc. (CAPR) under the STOCK Act: Roger Marshall.
When was CAPR most recently disclosed by Congress?
The most recent CAPR disclosure was a purchase by Roger Marshall on 27 July 2017.
What is the total disclosed congressional trading volume for CAPR?
Members of Congress have disclosed approximately $24K in CAPR purchases and $24K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in CAPR?
This CAPR page updates as soon as new STOCK Act disclosures are filed for Capricor Therapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.